AHFS Drug Information® 2023


Free access

List Price: $468.00

Member Price: $360.00

Page Count: 3504

AHFS® Drug Information® 2023 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. 

AHFS Drug Information 2023 is not available as an eBook. Learn more about related resources, electronic only monographs, and AHFS® Clinical Drug InformationTM here.

AHFS Drug Information® 2023 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.

Updates in the new edition:

  • Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
  • The latest information on the changing landscape of predominant COVID-19 subvariants and its effects on COVID therapeutics, including updated mRNA vaccine formulations, changes in emergency use authorization (EUA) status, and updated recommendations from the Infectious Diseases Society of America (IDSA), and the National Institutes of Health (NIH)
  • Contemporary topics such as new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
  • Inclusion of Standardize4Safety concentration standards for IV and oral liquid drugs
  • Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
  • Expanded content on off-label uses, real-word data, and long-term clinical data
  • Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
  • New content on gene therapies for the treatment of cancers and certain inherited disorders
  • The latest information from FDA safety communications regarding opioid pain medications and stimulant drugs
  • Addition of 60 new molecular entities (NMEs) and new therapeutic biological products approved since Jan 2023

Published under the Editorial Authority of ASHP®
American Society of Health-System Pharmacists®


Senior Vice President, Office of Professional Development and Publishing: Daniel J. Cobaugh, PharmD, DABAT, FAACT

AHFS Editor-in-Chief and Senior Editorial Director: Michael Gabay, PharmD, JD, BCPS, FCCP

Deputy Editor-in-Chief: Shingyee Cindy Huang, PharmD 

Principal Editorial Contributors: The University of Illinois at Chicago Drug Information Service and the University of Utah Drug Information Service

Editorial Contributors: Linda Bedford Arcuri, PharmD, Susan K. Braun, BS Pharm, Natalie A. Mendham, PharmD, Elaine K. Snow, BS Pharm, Karen M. Whalen, BS Pharm, BCPS, FASHP, and Barbara F. Young, PharmD, MHA

Contributors: Auburn University Drug Information Service, the University of Arizona Drug Information Service, the University of Kansas Drug Information Service, the University of Missouri, Kansas City Drug Information Service, and the University of Rhode Island Drug Information Service

Assistant Editor for Injectable Drug Information: Natalie C. Rosanelli, PharmD

Clinical Informatics Analyst: Kevin Son, PharmD, MHI

Project Manager: Elizabeth P. Shannon, BS



AHFS DI has maintained itself as a premier, evidence-based drug compendium. Even in the era of digital, online use, AHFS DI has evolved...and offers its information both in print and online.

What sets AHFS DI apart from the [other drug information books available] is its comparative, unbiased, evaluative drug information and its continually maintained relevance. It has been vetted through multiple channels of review and has consistently been recognized as the gold standard of where to obtain drug information.”

Patrick J. Scoble, PharmD, Doodys Review Service


"This book succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of today's healthcare professionals. The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field.

This reference can be used by any healthcare professional utilizing or prescribing medications in their practice, including physicians, pharmacists, physician assistants, and nurse practitioners. The book is so nicely organized and easily referenced that it can also be used by students in the medical, pharmacy, and nursing fields as well."

Melissa M. Potts, BS, PharmD, Doodys Review Service